Patent ID: 8236308

Claim:
A pharmaceutical composition for the treatment of a human patient, comprising a bispecific single chain antibody which comprises (i) a first binding domain binding to an epitope of human and non-chimpanzee primate CD3, and (ii) a second binding domain binding to a cell surface antigen, wherein the epitope is part of an amino acid sequence comprised in SEQ ID NOs. 134, 135 and 136, and comprises the amino acid sequence “FSEXE” (SEQ ID NO. 204), wherein “X” represents L (Leucine) or M (Methionine), wherein the bispecific single chain antibody comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence as shown in SEQ ID NOs. 70, 72, 78 or 80; (b) the amino acid sequence encoded by a nucleic acid sequence as shown in SEQ ID NOs. 69, 71, 77 or 79; and (c) the amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to the nucleotide sequence of (b).